Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal clinical study of Erythropoietin for the treatment of sudden cardiac arrest

Trial Profile

Pivotal clinical study of Erythropoietin for the treatment of sudden cardiac arrest

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erythropoietin (Primary)
  • Indications Reperfusion injury
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 09 Feb 2023 New trial record
  • 02 Feb 2023 According to a Rosalind Franklin University of Medicine and Science media release, pre-IND meeting carried out with the FDA's Division of Cardiology and Nephrology in the fourth quarter of 2022.
  • 02 Feb 2023 According to a Rosalind Franklin University of Medicine and Science media release, the company looking to finalize its IND application during the first quarter of 2023 and to initiate this study early next year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top